human pd 1  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    Name:
    PD 1 cDNA ORF Clone Human untagged
    Description:
    Full length Clone DNA of Human programmed cell death 1 PDCD1
    Catalog Number:
    hg10377-ut
    Product Aliases:
    CD279 cDNA ORF Clone Human, hPD-1 cDNA ORF Clone Human, hPD-l cDNA ORF Clone Human, hSLE1 cDNA ORF Clone Human, PD-1 cDNA ORF Clone Human, PD1 cDNA ORF Clone Human, SLEB2 cDNA ORF Clone Human
    Price:
    195.0
    Applications:
    Stable or Transient mammalian expression
    Size:
    1Unit
    Category:
    cDNA Clone
    Molecule Name:
    PDCD1,Pdc1,PD-1,
    Buy from Supplier


    Structured Review

    Sino Biological human pd 1
    A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of <t>PD-1</t> with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.
    Full length Clone DNA of Human programmed cell death 1 PDCD1
    https://www.bioz.com/result/human pd 1/product/Sino Biological
    Average 91 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    human pd 1 - by Bioz Stars, 2021-02
    91/100 stars

    Images

    1) Product Images from "Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients"

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

    Journal: JCI Insight

    doi: 10.1172/jci.insight.59125

    A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.
    Figure Legend Snippet: A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.

    Techniques Used: Binding Assay, Flow Cytometry, Cytometry, Staining, Injection, Transfection, Expressing

    The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).
    Figure Legend Snippet: The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).

    Techniques Used: Binding Assay, Flow Cytometry, Cytometry, Transfection, Staining, Recombinant

    2) Product Images from "Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients"

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

    Journal: JCI Insight

    doi: 10.1172/jci.insight.59125

    A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.
    Figure Legend Snippet: A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.

    Techniques Used: Binding Assay, Flow Cytometry, Cytometry, Staining, Injection, Transfection, Expressing

    The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).
    Figure Legend Snippet: The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).

    Techniques Used: Binding Assay, Flow Cytometry, Cytometry, Transfection, Staining, Recombinant

    Related Articles

    Transfection:

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
    Article Snippet: .. Expression plasmid for human PD-1 (catalog HG10377-UT, Sino Biological) was transfected into HEK293T cells using Lipofectamine 2000 (Life Technologies). .. Expression of PD-1 and nivolumab binding through human IgG4 were evaluated by flow cytometry.

    Selection:

    Article Title: Multi‑target inhibition by four tandem shRNAs embedded in homo‑ or hetero‑miRNA backbones.
    Article Snippet: .. The resultant lentiviruses were sequentially transduced into 293A cells, followed by selection of drug‑resistant colonies with 10 µg/ml blasticidin for BTLA expression, 0.25 µg/ml puromycin for PD1 expression, 500 µg/ml hygmycin for TIM3 expression and 1,000 µg/ml G418 for LAG3 expression. .. Each selection lasted for 10 days, and finally multi‑target‑overexpressing 293A cells were obtained and identified by flow cytometry.

    Expressing:

    Article Title: Multi‑target inhibition by four tandem shRNAs embedded in homo‑ or hetero‑miRNA backbones.
    Article Snippet: .. The resultant lentiviruses were sequentially transduced into 293A cells, followed by selection of drug‑resistant colonies with 10 µg/ml blasticidin for BTLA expression, 0.25 µg/ml puromycin for PD1 expression, 500 µg/ml hygmycin for TIM3 expression and 1,000 µg/ml G418 for LAG3 expression. .. Each selection lasted for 10 days, and finally multi‑target‑overexpressing 293A cells were obtained and identified by flow cytometry.

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
    Article Snippet: .. Expression plasmid for human PD-1 (catalog HG10377-UT, Sino Biological) was transfected into HEK293T cells using Lipofectamine 2000 (Life Technologies). .. Expression of PD-1 and nivolumab binding through human IgG4 were evaluated by flow cytometry.

    Plasmid Preparation:

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients
    Article Snippet: .. Expression plasmid for human PD-1 (catalog HG10377-UT, Sino Biological) was transfected into HEK293T cells using Lipofectamine 2000 (Life Technologies). .. Expression of PD-1 and nivolumab binding through human IgG4 were evaluated by flow cytometry.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91
    Sino Biological human pd 1
    A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of <t>PD-1</t> with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.
    Human Pd 1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pd 1/product/Sino Biological
    Average 91 stars, based on 3 article reviews
    Price from $9.99 to $1999.99
    human pd 1 - by Bioz Stars, 2021-02
    91/100 stars
      Buy from Supplier

    86
    Sino Biological human il10 gene
    A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of <t>PD-1</t> with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.
    Human Il10 Gene, supplied by Sino Biological, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human il10 gene/product/Sino Biological
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human il10 gene - by Bioz Stars, 2021-02
    86/100 stars
      Buy from Supplier

    N/A
    Full length Clone DNA of Human interleukin 7 receptor with C terminal Myc tag
      Buy from Supplier

    Image Search Results


    A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.

    Journal: JCI Insight

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

    doi: 10.1172/jci.insight.59125

    Figure Lengend Snippet: A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.

    Article Snippet: Expression plasmid for human PD-1 (catalog HG10377-UT, Sino Biological) was transfected into HEK293T cells using Lipofectamine 2000 (Life Technologies).

    Techniques: Binding Assay, Flow Cytometry, Cytometry, Staining, Injection, Transfection, Expressing

    The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).

    Journal: JCI Insight

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

    doi: 10.1172/jci.insight.59125

    Figure Lengend Snippet: The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).

    Article Snippet: Expression plasmid for human PD-1 (catalog HG10377-UT, Sino Biological) was transfected into HEK293T cells using Lipofectamine 2000 (Life Technologies).

    Techniques: Binding Assay, Flow Cytometry, Cytometry, Transfection, Staining, Recombinant

    A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.

    Journal: JCI Insight

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

    doi: 10.1172/jci.insight.59125

    Figure Lengend Snippet: A method for detection of nivolumab binding in T cells of NSCLC patients. ( A ) Flow cytometry staining of PD-1 with PD-1 detection antibody (EH12.1) in peripheral blood CD8 and CD4 T cells before injection (Pre) and 2 weeks after the first dose of nivolumab (Post 1). ( B ) PD-1–transfected HEK293T cells (HEK293T-PD-1) exhibited binding of EH12.1 (left). After treatment with nivolumab, EH12.1 binding was completely abolished, whereas the nivolumab detection antibody (anti-IgG4, HP6025) exhibited the original expression pattern (right). Data are representative of 3 independent experiments. ( C ) Staining of PD-1 by EH12.1 and IgG4 by HP6025 in CD8 and CD4 T cells from fresh whole blood and pleural effusion was evaluated by flow cytometry at pretreatment and 2 weeks after the initial dose of nivolumab. Whole blood from Pt. 1 and pleural effusion from Pt. 2 are shown as representative analyses. ( D ) Staining of PD-1 (EH12.1) and IgG4 (HP6025) in CD8 and CD4 T cells from fresh whole blood from Pt. 3 and pleural effusion from Pt. 4 were analyzed by flow cytometry at 34 weeks and 18 weeks after the final dose, respectively.

    Article Snippet: Expression plasmid for human PD-1 (catalog HG10377-UT, Sino Biological) was transfected into HEK293T cells using Lipofectamine 2000 (Life Technologies).

    Techniques: Binding Assay, Flow Cytometry, Cytometry, Staining, Injection, Transfection, Expressing

    The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).

    Journal: JCI Insight

    Article Title: Clinical implications of monitoring nivolumab immunokinetics in non–small cell lung cancer patients

    doi: 10.1172/jci.insight.59125

    Figure Lengend Snippet: The change in nivolumab-binding status can be mapped by flow cytometry. ( A ) Human PD-1–transfected HEK293T cells (HEK293T-PD-1) were treated with serial dilutions of nivolumab (10, 2, 0.4, 0.08, 0.016, and 0.0032 μg/ml), and the staining patterns of IgG4 and PD-1 detection antibodies and the capacity of recombinant PD-L1 binding (20 μg/ml) were evaluated. Data are representative of 3 independent experiments. ( B ) Schematics present 3 different binding statuses: complete binding (CB: red gate), partial binding (PB: blue gate), and no binding (NB: green gate). ( C ) Nivolumab binding was analyzed at 2 follow-up time points, as indicated, in fresh peripheral blood CD8 and CD4 T cells from each of 3 cases that discontinued treatment (Pt. 5–7).

    Article Snippet: Expression plasmid for human PD-1 (catalog HG10377-UT, Sino Biological) was transfected into HEK293T cells using Lipofectamine 2000 (Life Technologies).

    Techniques: Binding Assay, Flow Cytometry, Cytometry, Transfection, Staining, Recombinant